Company, Employee of: Eli Lilly and Company, Paul Emery Grant/research support from: Pfizer, MSD, AbbVie, Bristol-Myers Squibb, Roche, Consultant for: Pfizer, MSD, AbbVie, Bristol-Myers Squibb, UCB, Roche, Novartis, Gilead, Samsung, Sandoz and Lilly, Sreekumar Pillai Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Philip Helliwell Grant/research support from: Paid to charity: from AbbVie, Janssen and Novartis, Consultant for: Paid to charity: from AbbVie, Amgen, Pfizer, and UCB and Celgene. Paid to self: from Celgene and Galapagos

DOI: 10.1136/annrheumdis-2019-eular.8709

LB0006

SUBCUTANEOUS SECUKINUMAB 300MG AND 150MG PROVIDES SUSTAINED INHIBITION OF RADIOGRAPHIC PROGRESSION IN PSORIATIC ARTHRITIS OVER 2 YEARS: RESULTS FROM THE PHASE 3 FUTURE-5 TRIAL

Philip J. Mease¹, Robert B.M. Landewé², Proton Rahman³, Hasan Tahir⁴, Atul Singhal⁵, Elke Boettcher⁶, Sandra Navarra⁷, Aimee Readie⁸, Shephard Mpofu⁹, Eumorphia Maria Delicha⁹, Luminita Pricop⁹, Désirée van der Heijde¹⁰. ¹Swedish Medical Centre and University of Washington, Seattle, United States of America; ²University of Amsterdam and Atrium Medical Centre, Amsterdam, Netherlands; ³Memorial University, Newfoundland and Labrador, Canada; ⁴Whipps Cross Hospital, London, United Kingdom; ⁵Southwest Rheumatology, Dallas, United States of America; ⁶Rheumazentrum Favoriten, Vienna, Austria; ⁷University of Santo Tomas Hospital, Manila, Philippines; ⁸Novartis Pharmaceuticals Corp., East Hanover, United States of America; ⁹Novartis Pharma AG, Basel, Switzerland; ¹⁰Leiden University Medical Centre, Leiden, Netherlands

Background: Secukinumab (SEC) provided sustained clinical efficacy, and inhibition of radiographic progression over 52 Weeks (Wks) in patients (pts) with psoriatic arthritis (PsA) in the FUTURE 5 study¹.

Objectives: To report the effect of SEC on radiographic progression at Wk 104 (2 years) in PsA pts in the FUTURE 5 study.

Methods: Adults (N=996) with active PsA, stratified by prior anti-TNF therapy (naïve and inadequate response/intolerance [IR]) were randomised 2:2:2:3 to subcutaneous SEC 300mg with loading dose (LD; 300mg), 150mg LD (150mg), 150mg no LD, or placebo at baseline (BL), Wks 1, 2, 3, 4, and every 4 wks thereafter. Pts could have SEC dose escalated from 150 to 300 mg starting from Wk 52, based on physicians' judgement. Data are shown for pts originally randomised to SEC; 150mg groups include pts who had dose escalated to 300mg. Concomitant MTX (≤ 25 mg/week) was allowed. Radiographic progression (mean change in van der Heijde-modified total Sharp score [vdH-mTSS] and its components: erosion and joint space narrowing [JSN] scores, was based on hand/wrist/foot X-rays obtained at BL and Wk 104, and assessed by two blinded readers (plus an adjudicator if required). Other efficacy endpoints included ACR20/50, PASI90 and resolution of dactylitis and enthesitis.

Table. Summary of Efficacy Results

Mean change in vdH-mTSS scores from BL to Wk 104 (BL score)			
	300mg N=222 n=191	150mg group* N=220 n=181	150mg no LD group* N=222 n=169
vdH-mTSS	0.37 (12.07)	0.52 (11.47)	0.41 (13.99)
Erosion	0.27 (7.15)	0.27 (6.67)	0.38 (8.07)
JSN	0.11 (4.92)	0.24 (4.79)	0.03 (5.92)
Clinical responses at Wk 104 (% responders [n])			
	300 mg N = 222	150 mg group* N = 220	150 mg no LD group* N = 222
ACR20	77.0 (187)	79.4 (175)	78.0 (168)
ACR50	51.9 (187)	52.6 (175)	57.7 (168)
PASI90 ¹	70.1 (97)	59.2 (103)	62.6 (91)
Resolution of enthesitis ²	78.0 (118)	80.3 (117)	69.5 (95)
Resolution of dactylitis ³	82.8 (64)	85.5 (62)	89.3 (75)
Observed data			
* 150mg and 150mg no load arms include 86 and 92 pts, respectively, who were dose escalated at Wk 52 or later.			
N, number of pts randomised; n, number of pts with data at BL and Wk 104.			
Data from pts with: ¹ BL psoriasis $\geq 3\%$ body surface area, ² enthesitis at BL, ³ dactylitis at BL			

Results: Overall, 84.7% (300mg), 82.3% (150mg) and 75.2% (150mg no LD) pts completed 2 years of treatment. A total of 86 (39%) and 92 (41%) pts had their dose escalated to 300mg in the 150mg and 150mg no LD groups, respectively. Inhibition of radiographic progression was sustained with SEC through 2 years (Table 1). Proportions of pts with no radiographic progression (change from BL in mTSS ≤ 0.5) with SEC were 89.5% (300 mg), 82.3% (150 mg), and 81.1% (150 mg no LD) at 2 years; corresponding proportion of pts for change from BL in mTSS ≤ 0.0 were: 81.2%, 69.1% and 73.4%, respectively. Clinical responses were also sustained through 2 years (Table 1).

Conclusion: Subcutaneous secukinumab provided sustained inhibition of radiographic progression and sustained clinical responses through 2 years of treatment in pts with active PsA.

REFERENCE

[1] Mease PJ *et al. Arthritis Rheumatol* 2018;70(suppl 10).

Disclosure of Interests: Philip J Mease Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Leo, Eli Lilly, Merck, Novartis, Pfizer, Sun Pharmaceutical Industries, Inc., and UCB., Consultant for: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Galapagos, Gilead, Janssen, Leo, Eli Lilly, Merck, Novartis, Pfizer, Sun Pharmaceutical Industries, Inc., and UCB., Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Leo, Merck, Novartis, Pfizer and UCB., Robert B.M. Landewé: None declared, Proton Rahman Grant/research support from: Investigator for Janssen Research & Development, LLC and Novartis, Consultant for: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis, and UCB, Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, and Novartis, Hasan Tahir Grant/research support from: Novartis, Eli-Lilly, Speakers bureau: AbbVie, Janssen, Eli Lilly, and Novartis, Atul Singhal Grant/research support from: AAbbVie, Gilead, Sanofi, Regeneron, Amgen, Roche, BMS, Janssen, Lilly, Novartis, Pfizer, UCB, Astra Zeneca, MedImmune, Fujifilm, Nichi-Iko, Mallinckrodt, Speakers bureau: AbbVie, Elke Boettcher Consultant for: Amgen, Roche, Eli Lilly, Pfizer, MSD, Novartis, Speakers bureau: Amgen, Roche, Eli Lilly, Pfizer, MSD, Novartis, Sandra Navarra Speakers bureau: Astellas, Johnson & Johnson, Novartis, Pfizer, Aimee Readie Shareholder of: Novartis, Employee of: Novartis, Shephard Mpofu Shareholder of: Novartis, Employee of: Novartis, Eumorphia Maria Delicha Consultant for: Novartis, Luminita Pricop Shareholder of: Novartis, Employee of: Novartis, Désirée van der Heijde Consultant for: AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi, Eli-Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, Union Chimique Belge
DOI: 10.1136/annrheumdis-2019-eular.8808

LB0007

SUBCUTANEOUS TANEZUMAB FOR OSTEOARTHRITIS PAIN: A 24-WEEK PHASE 3 STUDY WITH A 24-WEEK FOLLOW UP

Francis Berenbaum¹, Francisco J. Blanco², Ali Guermazi³, Eric Vignon⁴, Kenji Miki⁵, Takaharu Yamabe⁶, Lars Viktrup⁷, Rod Junor⁸, William Carey⁸, Mark Brown⁶, Ken Verburg⁶, Christine West⁶. ¹Sorbonne Université, INSERM, AP-HP Hospital Saint Antoine, Paris, France; ²INIBIC-Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; ³Boston University School of Medicine, Boston, United States of America; ⁴Université Claude Bernard, Lyon, France; ⁵Osaka Yukioka College of Health Science, Hayaishi Hospital, Osaka, Japan; ⁶Pfizer Inc, Groton, United States of America; ⁷Eli Lilly & Company, Indianapolis, United States of America; ⁸Pfizer Ltd, Tadworth, United Kingdom

Background: Tanezumab, a monoclonal antibody against nerve growth factor, is in development for treatment of osteoarthritis (OA) pain.

Objectives: To assess efficacy and safety of tanezumab in patients with moderate to severe OA pain who have not responded to or cannot tolerate standard of care analgesics.

Methods: A randomized, double-blind, placebo-controlled study (24 week treatment; 24 week follow-up) was conducted in patients in Europe and Japan with moderate to severe OA pain of the knee or hip and history of insufficient pain relief or intolerance to acetaminophen, oral nonsteroidal anti-inflammatory drug, and either tramadol or opioids (or unwilling to take opioids). Patients received subcutaneous tanezumab (2.5 or 5 mg) or placebo at baseline, week 8, and week 16. Co-primary endpoints were change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain, WOMAC Physical Function, and Patient Global Assessment of OA (PGA-OA) scores at week 24. Safety, including independent adjudication of joint safety events, was assessed.

Results: Tanezumab 5 mg met all co-primary endpoints (Fig. 1). Tanezumab 2.5 mg met WOMAC Pain and Physical Function endpoints but not the PGA-OA endpoint; thus, this dose did not meet pre-specified efficacy criteria. The occurrence

of adverse events (AEs) and discontinuations due to AEs were similar across groups, though serious AEs occurred more frequently in both tanezumab groups relative to placebo. Two deaths in the 5 mg tanezumab group were deemed unrelated to treatment. The only AE occurring in ≥3% of patients in any group, and more frequently (>1% difference) in both tanezumab groups relative to placebo, was OA. Total joint replacements (TJR) occurred in 6.7%, 7.8%, and 7.0% of patients in the placebo, tanezumab 2.5 mg, and tanezumab 5 mg groups, respectively. Joint safety events, including TJRs, were mostly adjudicated as normal progression of OA (58/79; 73.4%). Pre-specified joint safety events occurred in 0% and 2.5% (n = 14) of patients in the placebo and tanezumab (2.5 mg = 1.8%; 5 mg = 3.2%) groups, respectively. These 14 events in the tanezumab groups included rapidly progressive OA (2.5 mg n = 4; 5 mg n = 8), subchondral insufficiency fracture (2.5 mg n = 1), and primary osteonecrosis (5 mg n = 1).

Table 2. Treatment-Emergent AEs During the Treatment Period (All Causalities)

N (%) of patients	Placebo N=282	Tanezumab 2.5 mg N= 283	Tanezumab 5 mg N= 284
AE	155 (55.0)	150 (53.0)	162 (57.0)
Serious AE	3 (1.1)	8 (2.8)	9 (3.2)
Discontinued study due to AE	2 (0.7)	5 (1.8)	1 (0.4)
Discontinued treatment but continued study	7 (2.5)	3 (1.1)	4 (1.4)
Common AEs ^a			
Arthralgia	34 (12.1)	27 (9.5)	23 (8.1)
Nasopharyngitis	25 (8.9)	31 (11.0)	22 (7.7)
Back pain	15 (5.3)	16 (5.7)	17 (6.0)
Headache	18 (6.4)	15 (5.3)	14 (4.9)
Osteoarthritis	5 (1.8)	9 (3.2)	13 (4.6)
Paraesthesia	5 (1.8)	5 (1.8)	12 (4.2)
Influenza	5 (1.8)	5 (1.8)	9 (3.2)
Fall	8 (2.8)	12 (4.2)	7 (2.5)
Pain in extremity	7 (2.5)	9 (3.2)	5 (1.8)

^a Occurring in ≥3% of patients in any group.

Conclusion: Tanezumab 5 mg significantly improved all co-primary endpoints of pain, physical function, and PGA-OA. Tanezumab 2.5 mg significantly improved pain and physical function, but did not reach significance on PGA-OA. AEs are consistent with previous studies of tanezumab in OA. A similar number of TJRs were reported across groups, though overall joint safety events were more frequent with tanezumab than placebo.

Disclosure of Interests: Francis Berenbaum Grant/research support from: TRB Chemedica (through institution), MSD (through institution), Pfizer (through institution), Consultant for: Novartis, MSD, Pfizer, Lilly, UCB, Abbvie, Roche, Servier, Sanofi-Aventis, Flexion Therapeutics, Expanscience, GSK, Biogen, Nordic, Sandoz, Regeneron, Gilead, Bone Therapeutics, Regulaxis, Peptinov, Paid instructor for: Sandoz, Speakers bureau: Novartis, MSD, Pfizer, Lilly, UCB, Abbvie, Roche, Servier, Sanofi-Aventis, Flexion Therapeutics, Expanscience, GSK, Biogen, Nordic, Sandoz, Regeneron, Gilead, Sandoz, Francisco J. Blanco Grant/research support from: Galapagos NV, Abbvie, Sanofi, Bristol MS, UCB, Novartis, Genentech Inc., Regeneron, Lilly, Celgene, Amgen, Janssen, Kiniksa Pharmaceuticals, Ltd., Tedec Meiji., Consultant for: Pfizer, Gebro, Bioiberica, Sanofi., Ali Guermazi Consultant for: AstraZeneca, Pfizer, TissueGene, Galapagos, Roche and Merck-Serono., Eric Vignon Consultant for: Pfizer/Eli Lilly, Kenji Miki Speakers bureau: Pfizer, Janssen, Ayumi, Hisamitsu, Takaharu Yamabe Shareholder of: Pfizer, Employee of: Pfizer, Lars Viktrup Shareholder of: Eli Lilly & Company, Grant/research support from: Astella, Lundbeck, Coloplast, Employee of: Ciba Geigy, Eli Lilly and Company (currently), Rod Junor Shareholder of: Pfizer, Employee of: Pfizer, William Carey Shareholder of: Pfizer, Employee of: J&J, Pfizer (currently), Mark Brown Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Ken Verbarg Shareholder of: Pfizer, Employee of: Pfizer, Christine West Shareholder of: Pfizer, Employee of: Pfizer

DOI: 10.1136/annrheumdis-2019-eular.8660

LB0008

THE EFFECT OF HLA-DRB1 RISK ALLELES ON THE CLINICALEFFICACY OF ABATACEPT AND ADALIMUMAB IN SEROPOSITIVE BIOLOGIC-NAÏVE PATIENTSWITH EARLY, MODERATE-TO-SEVERE RA: DATA FROM A HEAD-TO-HEAD SINGLE-BLINDED TRIAL

William Rigby¹, Jane Buckner², Lou Bridges³, Marleen Nys⁴, Sheng Gao⁵, Martin Polinsky⁵, Alyssa Johnsen⁵, Neelanjana Ray⁵, Vivian Bykerk^{6,†} Dartmouth-Hitchcock Medical Center, Lebanon, United States of America; ²Benaroya Research Institute, Seattle, United States of America; ³University of Alabama School of Medicine, Birmingham, United States of America; ⁴Bristol-Myers Squibb, Braine-l'Alleud, Belgium; ⁵Bristol-Myers Squibb, Princeton, United States of America; ⁶Hospital for Special Surgery, New York, United States of America

Background: Mechanistic differences between biologics are poorly understood. *HLA-DRB1* alleles containing the shared epitope (SE), which are strongly associated with RA, are present in 85% of anti-cyclic citrullinated protein 2 (anti-CCP2) + patients (pts) with RA (Jiang *et al. Arthritis Rheumatol* 2015). In a prior retrospective exploratory analysis, abatacept (ABA) was more effective in SE+ vs SE- pts (Oryoji *et al. Ann Rheum Dis* 2017). Head-to-head (H2H) comparisons with other agents are lacking.

Objectives: This H2H, single-blinded trial (NCT02557100) in biologic-naïve pts with early, active RA prospectively explored the relationship between *HLA-DRB1* SE and the clinical efficacy of ABA or adalimumab (ADA).

Methods: Adults with early (=12 mths from symptom onset), moderate-to-severe RA (ACR/EULAR 2010 criteria) seropositive for anti-CCP2 (>3x ULN) and RF, were randomised 1:1 to SC ABA 125mg w/ky or SC ADA 40mg every 2 wks (both with stable, oral MTX w/ky) for 24 wks. Pts were grouped by SE status (+/-) based on *HLA-DRB1* genotype (-: no SE allele; +: =1 SE allele). Safety was analysed throughout the trial and up to 8 wks post last study drug dose. Clinical efficacy was assessed at Wk24 to determine the proportion of ACR20/50/70 responders in ABA vs ADA arms, and the adjusted mean changes from baseline in DAS28 (CRP), SDAI and CDAI. Treatment (tmt) differences between ABA and ADA in SE+ and SE- pts were assessed for ACR20/50/70 responders and DAS28 (CRP) remission at Wk24.

Results: 80 pts were treated: 40 ABA (9 SE-, 30 SE+, 1 SE unknown) and 40 ADA (9 SE-, 31 SE+). Baseline characteristics were balanced. Mean (SD) age, disease duration and DAS28 (CRP) were 46.0 (14.4) years, 5.5 (2.6) mths and 5.2 (1.1), respectively; 75% were female. No new safety signals were identified. In each arm, related AEs (ABA: 12 [30%]; ADA: 11 [27.5%]) and related serious AEs (ABA: 0; ADA: 1 [2.5%]) were similar. Numerically higher efficacy responses were seen with ABA vs ADA at Wk24 (Table 1). Similar results were observed for DAS28 (CRP), SDAI and CDAI. In SE+ pts, numerically higher efficacy responses were seen with ABA vs ADA at Wk24; 95% CI for estimated tmt differences for ACR20/50/70 responses and DAS28 (CRP) remission did not cross 0 (Figure 1).

Conclusion: In this seropositive early RA population, numerically higher efficacy responses were seen with abatacept vs adalimumab after 24wks of tmt, with more pronounced tmt differences in SE+ pts. Results are consistent with a previous

Table 1. Clinical outcomes at Wk24: as-treated analysis population

Clinical outcome	ABA (n=40)	ADA (n=40)	Estimate of difference for ABA vs ADA (95% CI)
ACR responses			
ACR20	83 (67, 93)	63 (46, 77)	20 (-3, 42)
ACR50	70 (54, 83)	45 (29, 62)	25 (2, 46)
ACR70	48 (32, 64)	30 (17, 47)	17.5 (-6, 39)
DAS28 (CRP)			
Adjusted mean change* (95% CI)	-2.6 (-2.9, -2.2)	-2.4 (-2.7, -2.1)	0.2 (-0.6, 0.3)†
Remission	48 (32, 64)	30 (17, 47)	17.5 (-6, 39)
SDAI			
Adjusted mean change* (95% CI)	-27.4 (-29.9, -24.9)	-26.1 (-28.7, -23.5)	-1 (-5, 2)†
Remission	35 (21, 52)	23 (11, 39)	12.5 (-11, 35)
CDAI			
Adjusted mean change* (95% CI)	-27.1 (-29.5, -24.7)	-25.0 (-27.5, -22.6)	-2 (-5.5, 1)†

Data are % (95% CI) unless stated otherwise. Estimates of adjusted mean change are from a repeated measures mixed model which includes baseline value, treatment group, time and time by treatment group interaction. Missing values were imputed as non-responders. DAS28 (CRP) remission: DAS28 (CRP) <2.6. SDAI remission: SDAI ≤3.3

*From baseline. †Adjusted mean difference for ABA vs ADA (95% CI).

ABA=abatacept; ACR20/50/70=20/50/70% improvement in ACR criteria; ADA=adalimumab

Figure 1. Clinical outcomes in ABA- vs ADA-treated pts at Wk 24 by SE genotype: as-treated analysis population

m indicates the number of patients with a response; n indicates the number of patients in the group. Patients with missing data for efficacy parameters at Week 24 are imputed as non-responders
ABA=abatacept; ACR20/50/70=20/50/70% improvement in ACR criteria; ADA=adalimumab; SE=shared epitope

study in which greater efficacy was seen with abatacept, but not TNF inhibitors, in anti-CCP2+ vs anti-CCP2- pts with RA (Harrold *et al.* *J Rheumatol* 2018).

Acknowledgement: Marianne Peluso (protocol manager); medical writing: Lola Parfitt (Caudex; funding: BMS)

Disclosure of Interests: William Rigby Consultant for: AbbVie, BMS, Genentech and Pfizer, Jane Buckner Grant/research support from: Janssen, Bristol-Myers Squibb (current); Novo Nordisk, Pfizer, Eli Lilly (past), Consultant for: Bristol-Myers Squibb, Eli Lilly, Lou Bridges: None declared, Marleen Nys Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, Sheng Gao Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, Martin Polinsky Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, Alyssa Johnsen Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, Neelanjana Ray Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, Vivian Bykerk Grant/research support from: Mallinckrodt, BMS, Crescendo Biosciences, Sanofi/Regeneron, Consultant for: Amgen, Pfizer, UCB, Scipher, Sanofi/Genzyme/Regeneron

DOI: 10.1136/annrheumdis-2019-eular.8668

LB0009

FIRST-IN-HUMAN STUDY OF NOVEL IMPLANTED VAGUS NERVE STIMULATION DEVICE TO TREAT RHEUMATOID ARTHRITIS

Mark C. Genovese¹, Norman Gaylis², David Sikes³, Alan Kivitz⁴, Diane M Horowitz⁵, Charles Peterfy⁶, Yaakov Levine⁷, David Chernoff⁷. ¹Stanford University School of Medicine, Stanford, United States of America; ²Arthritis and Rheumatic Disease Specialties, Aventura, United States of America; ³Florida Medical Clinic, Zephyrhills, United States of America; ⁴Altoona Center for Clinical Research, Duncansville, United States of America; ⁵Northwell Health, Great Neck, United States of America; ⁶Spire Sciences, Boca Raton, United States of America; ⁷SetPoint Medical, Valencia, United States of America

Background: The inflammatory reflex plays a role in regulating innate and adaptive immunity through cellular and molecular pathways¹. Activation of this neuro-immune reflex by electrical vagus nerve stimulation (VNS) reduced systemic inflammation and improved disease activity in a 17 subject rheumatoid arthritis (RA) proof-of-concept study using a reprogrammed epilepsy stimulator². A novel miniaturized neurostimulator, the "MicroRegulator" (MR), was developed for a first-in-human pilot study in multi-drug refractory RA.

Objectives: To assess the safety and efficacy of the MR in a double-blind study in active RA patients.

Methods: The MR was implanted in 14 patients with active RA and prior insufficient response to ≥ 2 bDMARDs or JAK inhibitors with ≥ 2 different modes of action; all patients remained on stable background of methotrexate. Three weeks after implantation, the first 3 subjects were stimulated 1 min QD and, following safety review board approval, the remaining 11 patients were implanted with the MR and randomized to 1 min of sham, QD, or QID stimulations for 12 weeks. Patients, rheumatologists, joint assessors and monitors were fully blinded to treatment arm. Subjects randomized to sham had their devices activated after the primary endpoint at 12 weeks. Clinical efficacy was measured by DAS28-CRP response and contrast-enhanced MRI (RAMRIS OMERACT). The pharmacodynamic response to VNS was assessed in blood using cytokine production in an ex-vivo bioassay (TruCulture).

Results: 14 patients were enrolled (mean prior bDMARDs= 4.8, mean DAS28-CRP= 5.94). Implantation and stimulation were generally well tolerated. There were no device or treatment-related SAEs and 2 surgery related adverse events (left vocal cord paralysis, Horner's syndrome) that resolved without clinically significant sequelae. DAS28-CRP change at week 12 was (mean $\pm$ SEM): Open label QD= -1.44 ± 0.64 , QD= -1.24 ± 0.88 , QID= 0.38 ± 0.71 , Sham= 0.16 ± 0.21 . Of QD stimulated patients, 4 of 6 had a EULAR good or moderate response. MRI measures of synovitis or osteitis did not change after 12 weeks of stimulation. RAMRIS erosion scores correlated with EULAR response (change $\pm$ SEM in erosion scores in EULAR responders = -2.2 ± 1.4 vs. 2.4 ± 0.96 in EULAR non-responders). The pharmacodynamic response to VNS was confirmed in actively stimulated groups with $>30\%$ decrease from baseline in bioassay levels of IL-1 β , IL-6, and TNF- α at week 12.

Conclusion: The novel MR device and stimulation was well tolerated independent of the two surgery-related events. MR associated stimulation reduced signs and symptoms of RA in a meaningful number of highly drug-refractory subjects. No clinical improvement was observed in the sham group. These initial pilot data support the use of the MR in a larger blinded sham-controlled study in patients who have failed biologics or targeted oral therapies as a novel approach for treatment of RA and other chronic inflammatory diseases.

REFERENCES:

- Andersson U, Tracey K, Annu. Rev. Immunol. 2012; 30:313.
- Koopman, F, et. al. PNAS. 2016; 113(29):8284

Disclosure of Interests: Mark C. Genovese Grant/research support from: Sanofi/Genzyme, Genentech/Roche, RPharm, Consultant for: Sanofi/Genzyme, Genentech/Roche, RPharm, Norman Gaylis Grant/research support from: Multiple clinical research trials, BMS, AbbVie, GSK, Janssen, Amgen, Pfizer, Regeneron, UCB, Sanofi, SetPoint, ImmunPharma, Astra Zeneca, Sandoz, Novartis, Gilead, Consultant for: electroCore, David Sikes Grant/research support from: SetPoint Medical/Pfizer/Actelion/AbbVie/Eli Lilly, Alan Kivitz Shareholder of: Novartis, Consultant for: Abbvie, Janssen, Pfizer, UCB, Genzyme, Sanofi, Regeneron, Boehringer Ingelheim, Sun Pharma Advanced Research, Flexion, Paid instructor for: Celgene, Horizon, Merck, Novartis, Pfizer, Genzyme, Sanofi, Regeneron, Speakers bureau: Celgene, Horizon, Merck and Genetech, Flexion, Diane M Horowitz Grant/research support from: SetPoint Medical, Charles Peterfy Shareholder of: Spire Sciences, Inc, Consultant for: AbbVie, Actera, Amgen, AstraZeneca, Bristol-Myers Squibb, Centrexion, Daiichi Sankyo, Five Prime Therapeutics, Genentech, Hoffmann-La Roche, Janssen, Lilly USA, MedImmune, Merck, Novartis, Plexikon, Pfizer, Sanofi, Salix-Santarus, Samsung, Employee of: Spire Sciences, Inc, Speakers bureau: Amgen, Yaakov Levine Shareholder of: SetPoint Medical, Employee of: SetPoint Medical, David Chernoff Shareholder of: SetPoint Medical, Consultant for: Crescendo BioScience, Employee of: SetPoint Medical
DOI: 10.1136/annrheumdis-2019-eular.8716

LB0010

ULTRA-LOW DOSES OF RITUXIMAB OR RETREATMENT OF RHEUMATOID ARTHRITIS: A RANDOMISED CONTROLLED NON-INFERIORITY TRIAL

L.M. Verhoeve¹, Nathan den Broeder², R.M. Thurlings³, W.H. van der Laan⁴, W. van der Weele⁵, Marc Kok⁵, H.J. Bemmelot Moens⁵, Thasia Woodworth⁵, Bart van den Bemt⁶, Frank van den Hoogen⁵, Alfons den Broeder⁵. ¹Sint Maartenskliniek, Rheumatology, Nijmegen, Netherlands; ²Radboudumc, Rheumatology, Nijmegen, Netherlands; ³Reade, Rheumatology, Amsterdam, Netherlands; ⁴Maasstad hospital, Department of Rheumatology and Clinical Immunology, Rotterdam, Netherlands; ⁵Ziekenhuisgroep Twente, Rheumatology, Almelo, Netherlands; ⁶David Geffen School of Medicine, University of California, Division of Rheumatology, Los Angeles, United States of America; ⁷Sint Maartenskliniek, Pharmacy, Nijmegen, Netherlands; ⁸Radboudumc, Pharmacy, Nijmegen, Netherlands

Background: Rituximab (RTX) is an effective treatment for patients with Rheumatoid Arthritis (RA). 1000mg (1 $\times$ 1000mg or 2 $\times$ 500mg) has similar 6-month efficacy as the registered dose of 2 $\times$ 1000mg. Based on several case reports and